Venture Life Group (LON:VLG) Stock Price Crosses Above 50-Day Moving Average – Time to Sell?

Venture Life Group plc (LON:VLG) passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 60.91 and traded as high as GBX 68. Venture Life Group shares last traded at GBX 66, with a volume of 763,578 shares.

Venture Life Group Stock Performance

The company has a market capitalization of £80.41 million, a P/E ratio of 15.10, a P/E/G ratio of 5.67 and a beta of 0.23. The company has a debt-to-equity ratio of 0.82, a current ratio of 4.71 and a quick ratio of 1.48. The stock’s 50 day simple moving average is GBX 60.91 and its two-hundred day simple moving average is GBX 64.40.

Venture Life Group (LON:VLG) last announced its earnings results on Tuesday, March 31st. The company reported GBX (1.49) earnings per share for the quarter. Venture Life Group had a return on equity of 7.82% and a net margin of 17.42%.The company had revenue of GBX 3,517 million during the quarter. As a group, research analysts expect that Venture Life Group plc will post 6.1391542 earnings per share for the current year.

Insider Buying and Selling at Venture Life Group

In related news, insider Paul McGreevy bought 48,373 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was bought at an average cost of GBX 62 per share, with a total value of £29,991.26. Insiders have bought 80,207 shares of company stock valued at $5,004,160 over the last ninety days. Insiders own 7.27% of the company’s stock.

Venture Life Group Company Profile

Venture Life is an international consumer self-care company focused on developing and commercialising products for the global self-care market helping our consumers live a longer healthier and more rewarding life.

Headquartered in the UK, the Group’s product portfolio includes Balance Activ in the area of women’s intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally.